高级检索
当前位置: 首页 > 详情页

High-Fat Mouse Model to Explore the Relationship between Abnormal Lipid Metabolism and Enolase in Pancreatic Cancer

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Endocrinology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, China. [2]School of Pharmaceutical Science, Kunming Medical University, Kunming, Yunnan 650500, China. [3]School of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicine Utilization, Yunnan University of Chinese Medicine, Kunming, Yunnan 650500, China. [4]Yunnan Province Clinical Research Center for Metabolic diseases, Kunming, Yunnan 650000, China. [5]Yunnan Clinical Medical Center for Endocrine and Metabolic Diseases, Kunming, Yunnan 650000, China. [6]Affiliated Hospital of Yunnan University, Qingnian Road, Kunming, Yunnan 650000, China.
出处:
ISSN:

摘要:
Malignant tumors have become a major social health problem that seriously threatens human health, among which pancreatic cancer has a high degree of malignancy, difficult diagnosis and treatment, short survival time, and high mortality. More and more attention has been paid to abnormal lipid metabolism as a momentous carcinogenesis mechanism. Here, we explored the relationship between abnormal lipid metabolism, enolase, and pancreatic cancer by clinical data analysis. A high-fat mouse model was constructed, and then, a subcutaneous tumorigenesis mouse model of carcinoma of pancreatic cells and a metastatic neoplasm mouse pattern of pancreatic carcinoma cells injected through the tail vein were constructed to explore whether abnormal lipid metabolism affects the progression of pancreatic cancer in mice. We constructed a high-lipid model of pancreatic carcinoma cell lines and knockdown and overexpressed enolase in pancreatic carcinoma cell lines and investigated whether high lipid regulates epithelial-mesenchymal transition (EMT) by upregulating enolase (ENO), thereby promoting the cells of pancreatic carcinoma to invade and migrate. Triglycerides, total cholesterol, free cholesterin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and neuron-specific enolase (NSE) from pancreatic cancer patients and nonpancreatic cancer patients were tested. The differences in blood lipids between patients with and without pancreatic carcinoma were compared, and the correlation between blood lipids and neuron-specific enolase was analyzed. We confirmed that the serum triglyceride level of pancreatic cancer patients at initial diagnosis is overtopping nonpancreatic cancer patients, and the neuron-specific enolase level of patients with pancreatic carcinoma is better than nonpancreatic carcinoma sufferers. Triglyceride level is positively correlated with neuron-specific enolase level, and serum triglyceride level has predictive value for pancreatic cancer. Hyperlipidemia can promote tumor growth and increase the expression levels of ENO1, ENO2, and ENO3 in subcutaneous tumor formation of pancreatic cancer in mice. Additional hyperlipidemia promoted pancreatic carcinoma metastasis in the lung in mice injected through the tail vein, which confirmed that hyperlipidemia accelerated the process of EMT by increasing the expression of ENO1, ENO2, and ENO3, therefore promoting the pancreatic cancer cell metastasis.Copyright © 2023 Lin Qin et al.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 3 区 细胞生物学 3 区 免疫学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 细胞生物学 3 区 免疫学
JCR分区:
出版当年[2023]版:
Q2 CELL BIOLOGY Q2 IMMUNOLOGY
最新[2023]版:
Q2 CELL BIOLOGY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Department of Endocrinology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, China. [2]School of Pharmaceutical Science, Kunming Medical University, Kunming, Yunnan 650500, China. [3]School of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicine Utilization, Yunnan University of Chinese Medicine, Kunming, Yunnan 650500, China. [4]Yunnan Province Clinical Research Center for Metabolic diseases, Kunming, Yunnan 650000, China. [5]Yunnan Clinical Medical Center for Endocrine and Metabolic Diseases, Kunming, Yunnan 650000, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Endocrinology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, China. [4]Yunnan Province Clinical Research Center for Metabolic diseases, Kunming, Yunnan 650000, China. [5]Yunnan Clinical Medical Center for Endocrine and Metabolic Diseases, Kunming, Yunnan 650000, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59104 今日访问量:0 总访问量:1875 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)